Navigation Links
Vivakor Divisions Continue to Demonstrate Independent Growth

CORALVILLE, Iowa, Dec. 15 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) Several of Vivakor's divisions have reported strong performance in 2009. Vivakor is a transdisciplinary hub of research and development with divisional spokes developing multiple products and technologies for market. Vivakor's R&D Product Pipeline strategy is anchored to the concept of licensing and strategic partnering. From idea inception, Vivakor's R&D efforts target commercialization and product-specific exit strategies to increase revenue potential from each new Vivakor technology. With a multi-million dollar purchase commitment in its nutraceutical division, new market opportunities and distribution agreements for its VivaThermic division's cryovials and continued growth in optics and MRI technology, the continued success of each of these divisions is seen as strong validation for the business model.

Executive Chairman Matt Nicosia was quoted: "Vivakor has made great strides in 2009. With the recent successes in several of our divisions, we are certain that the value proposition of our company will continue to increase. We expect continued success on several tracks and expect 2010 to be our most successful in terms of commercial success and equity value perspectives. Our greatest strength is from our diversity."

About Vivakor, Inc.

Vivakor is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at


This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and markets and business strategies. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.


Vivakor Investor Relations

c/o IME Advisors

(888) 648-8485

SOURCE Vivakor, Inc.

SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
2. Vivakor Announces New Acquisition Strategy
3. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
4. Reported Use of AMAGs Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are On the Verge of Use
5. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
6. instaCare Corp. Continues Turnaround, Reports 58% Revenues Increase for First Three Quarters
7. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
8. The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018
9. Health Care Retail Clinics Continue Gradual Expansion Through 2012: Deloitte Center for Health Solutions Report
10. Biotechnology Salutes Americas Veterans; Innovations Continue to Offer Improved Treatment and Care of Combat Troops
11. Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood ... people struggling with eating disorders as a result of the $20,000 raised at ... held at Fox Run Golf Club in Eureka, will help individuals who otherwise ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... Florida (PRWEB) , ... November 25, 2015 , ... ... LLC has announced that it has undertaken significant expansion of its current state ... The investment is part of PharmaTech’s strategy to increase its manufacturing capacity as ...
Breaking Medicine News(10 mins):